{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:03:51Z","timestamp":1790798631195,"version":"4.1.0"},"reference-count":32,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n \n In South Africa, the metastatic response rate for stage 4 high-risk neuroblastoma (HR-NB) to induction chemotherapy is lower than that of similar regimens in well-resourced settings. Augmenting current induction chemotherapy regimens with molecular radiotherapy, without increasing toxicity, is an attractive systemic treatment in radioisotope-avid tumors, especially in a resource-limited setting where stem cell transplantation and immunotherapy are unavailable and costly. Clinical trials of [\n 177<\/jats:sup>\n Lu]Lutetium DOTATATE ([\n 177<\/jats:sup>\n Lu]Lu-DOTATATE) have primarily focused on refractory or relapsed HR-NB, with disappointing results.\n \n This study evaluates the feasibility and dose-limiting toxicity grading of adding a single dose of [\n 177<\/jats:sup>\n Lu]Lu-DOTATATE to induction chemotherapy in achieving metastatic remission rates.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n \n The aim of the proof-of-concept, open-label study is to evaluate the safety and efficacy of induction [\n 177<\/jats:sup>\n Lu]Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) on postinduction response rate in children diagnosed with HR-NB. The primary objectives are to evaluate the dose-limiting toxicity profile of participants treated with induction [\n 177<\/jats:sup>\n Lu]Lu-DOTATATE PRRT in conjunction with standard induction chemotherapy; to evaluate the dosimetry in South African patients receiving induction [\n 177<\/jats:sup>\n Lu]Lu-DOTATATE PRRT; and to evaluate the feasibility related to resources in patients treated with induction [\n 177<\/jats:sup>\n Lu]Lu-DOTATATE PRRT in conjunction with standard induction chemotherapy. The secondary objective is to determine the postinduction metastatic response rate in patients diagnosed with HR-NB after receiving induction [\n 177<\/jats:sup>\n Lu]Lu-DOTATATE PRRT in conjunction with standard induction chemotherapy.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n The LuDO-SA trial is a phase 1, open-label, multicenter, 2-arm, randomized controlled clinical trial. Children aged 18 months to 18 years are eligible. The experimental arm, consisting of a single dose of [\n 177<\/jats:sup>\n Lu]Lu-DOTATATE after cycle 1 of OJEC (vincristine, carboplatin, etoposide, and cyclophosphamide) and OPEC (vincristine, cisplatin, etoposide, and cyclophosphamide) chemotherapy, will be compared to the standard arm of OJEC and OPEC chemotherapy. The postinduction metastatic response rate is based on the International Neuroblastoma Response Criteria (INRC). The statistical analysis will be descriptive. The Fisher exact test will be used to evaluate the significance of end-of-trial outcomes.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The trial received institutional ethics approval from 4 South African universities in 2022 and SAHPRA (South African Health Products Regulatory Authority) regulatory approval. The trial, funded by Kinderkankerfonds vzw and the UZA Foundation, commenced recruitment in January 2023. As of July 2026, a total of 15 patients have been enrolled across 4 academic hospital sites. Recruitment is projected to be completed by June 2027, with results expected to be published in December 2027.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n In this paper, we present the protocol of the LuDO-SA trial. The rationale and design of the trial in a resource-limited setting and its use in first-line regimens are discussed, and the current status of international [\n 177<\/jats:sup>\n Lu]Lu-DOTATATE molecular radiotherapy trials is summarized.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/93547","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:43:45Z","timestamp":1790797425000},"page":"e93547-e93547","source":"Crossref","is-referenced-by-count":0,"title":["[177Lu]Lu-DOTATATE Molecular Radiotherapy During Induction Chemotherapy for First-Line Stage 4 High-Risk Neuroblastoma in South African Children: Protocol for a Phase 1 Randomized Controlled Trial (LuDO-SA Trial)"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4502-1169","authenticated-orcid":false,"given":"Jaques","family":"van Heerden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6838-0180","authenticated-orcid":false,"given":"Mariana","family":"Kruger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1511-1478","authenticated-orcid":false,"given":"Kershinee","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3370-0874","authenticated-orcid":false,"given":"Anel","family":"van Zyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2810-0543","authenticated-orcid":false,"given":"James","family":"Warwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7288-6790","authenticated-orcid":false,"given":"Celeste","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6289-9512","authenticated-orcid":false,"given":"Tumelo","family":"Moalosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6720-1101","authenticated-orcid":false,"given":"Christoffel","family":"van Reenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4646-4332","authenticated-orcid":false,"given":"Alan","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0634-6339","authenticated-orcid":false,"given":"Khanyisile","family":"Hlongwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5267-1256","authenticated-orcid":false,"given":"Daniella","family":"Violante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2001-1304","authenticated-orcid":false,"given":"Nanette","family":"Bruwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4412-3825","authenticated-orcid":false,"given":"Gita","family":"Naidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8161-0596","authenticated-orcid":false,"given":"Biance","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4146-2485","authenticated-orcid":false,"given":"Lizette","family":"Louw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6627-603X","authenticated-orcid":false,"given":"Bronwin","family":"van Wyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5643-1553","authenticated-orcid":false,"given":"Mariza","family":"Vorster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2911-017X","authenticated-orcid":false,"given":"Thokozani","family":"Mkhize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8658-2379","authenticated-orcid":false,"given":"Anita","family":"Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"4","key":"R1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S1470-2045(12)70569-7","article-title":"Challenges for paediatric oncology in Africa","volume":"14","author":"Harif","journal-title":"Lancet Oncol"},{"issue":"8","key":"R2","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1002\/pbc.25501","article-title":"SIOP-PODC adapted risk stratification and treatment guidelines: recommendations for neuroblastoma in low- and middle-income settings","volume":"62","author":"Parikh","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"R3","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27944","article-title":"Overall survival for neuroblastoma in South Africa between 2000 and 2014","volume":"66","author":"Van Heerden","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"R4","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/bjc.2016.302","article-title":"Factors associated with recurrence and survival length following relapse in patients with neuroblastoma","volume":"115","author":"Basta","journal-title":"Br J Cancer"},{"issue":"4","key":"R5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00383-020-04627-x","article-title":"The importance of local control management in high-risk neuroblastoma in South Africa","volume":"36","author":"van Heerden","journal-title":"Pediatr Surg Int"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.02.003","article-title":"Predictors of differential response to induction therapy in high-risk neuroblastoma: a report from the Children\u2019s Oncology Group (COG)","volume":"112","author":"Pinto","journal-title":"Eur J Cancer"},{"issue":"3","key":"R7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/MPH.0000000000001369","article-title":"Advances in anti-GD2 immunotherapy for treatment of high-risk neuroblastoma","volume":"41","author":"Voeller","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"R8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.4143\/crt.2016.511","article-title":"Topotecan-vincristine-doxorubicin in stage 4 high-risk neuroblastoma patients failing to achieve a complete metastatic response to rapid COJEC: a SIOPEN study","volume":"50","author":"Amoroso","journal-title":"Cancer Res Treat"},{"issue":"12","key":"R9","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S1470-2045(18)30578-3","article-title":"Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial","volume":"19","author":"Ladenstein","journal-title":"Lancet Oncol"},{"issue":"3","key":"R10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/s0167-8140(85)80029-3","article-title":"The radiobiology of human neuroblastoma","volume":"3","author":"Deacon","journal-title":"Radiother Oncol"},{"issue":"4","key":"R11","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11040270","article-title":"Nuclear medicine imaging in neuroblastoma: current status and new developments","volume":"11","author":"Samim","journal-title":"J Pers Med"},{"issue":"7","key":"R12","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.2967\/jnumed.110.085100","article-title":"177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma","volume":"52","author":"Gains","journal-title":"J Nucl Med"},{"issue":"11","key":"R13","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s00259-013-2510-z","article-title":"Toxicity of upfront \u00b9\u00b3\u00b9I-metaiodobenzylguanidine (\u00b9\u00b3\u00b9I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis","volume":"40","author":"Bleeker","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"R14","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.nucmedbio.2008.05.002","article-title":"Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma","volume":"35 Suppl 1","author":"DuBois","journal-title":"Nucl Med Biol"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1007\/BF01249633","article-title":"Molybdenum-99 production in South Africa","volume":"23","author":"Iturralde","journal-title":"Eur J Nucl Med"},{"issue":"supplement 1","key":"R16","first-page":"307","volume":"59","author":"Chen","journal-title":"J Nucl Med"},{"issue":"2","key":"R17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/MPH.0000000000000411","article-title":"Initial experience with gallium-68 DOTA-Octreotate PET\/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma","volume":"38","author":"Kong","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"R18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.clon.2020.11.007","article-title":"Paediatric molecular radiotherapy: challenges and opportunities","volume":"33","author":"Aldridge","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"10","key":"R19","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1007\/s00259-020-04741-x","article-title":"A phase IIa trial of molecular radiotherapy with 177-lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma","volume":"47","author":"Gains","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"R20","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-022-00436-4","article-title":"Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [Lu]Lu-DOTATATE","volume":"9","author":"Malcolm","journal-title":"EJNMMI Phys"},{"issue":"7","key":"R21","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/RLU.0000000000003577","article-title":"Feasibility and therapeutic potential of combined peptide receptor radionuclide therapy with intensive chemotherapy for pediatric patients with relapsed or refractory metastatic neuroblastoma","volume":"46","author":"Fathpour","journal-title":"Clin Nucl Med"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1615136","article-title":"Role of F-AlF-NOTATATE PET\/CT in selecting pediatric neuroblastoma candidates for Lu-DOTATATE peptide receptor radionuclide therapy","volume":"12","author":"Liu","journal-title":"Front Med (Lausanne)"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.836230","article-title":"A phase II trial of a personalized, dose-intense administration schedule of lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma-LuDO-N","volume":"10","author":"Sundquist","journal-title":"Front Pediatr"},{"issue":"1","key":"R24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2174\/1874471011666171215093112","article-title":"Review: the role of radiolabeled DOTA-conjugated peptides for imaging and treatment of childhood neuroblastoma","volume":"11","author":"Alexander","journal-title":"Curr Radiopharm"},{"issue":"2","key":"R25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","journal-title":"N Engl J Med"},{"issue":"1","key":"R26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s00259-020-04873-0","article-title":"Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study","volume":"48","author":"Paganelli","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.013","article-title":"Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients","volume":"76","author":"Kraal","journal-title":"Eur J Cancer"},{"issue":"3","key":"R28","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1055\/s-0045-1812305","article-title":"Individualized dosimetry to guide LuTATE therapy in pediatric neuroblastoma","volume":"24","author":"London","journal-title":"World J Nucl Med"},{"issue":"3","key":"R29","doi-asserted-by":"publisher","first-page":"502","DOI":"10.2967\/jnumed.117.195883","article-title":"Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: a children\u2019s oncology group and SIOPEN group report on SIOPEN\/HR-NBL1","volume":"59","author":"Yanik","journal-title":"J Nucl Med"},{"key":"R30","unstructured":"Protection of Personal Information Act 4 of 2013. The Presidency, Republic of South Africa; 2013. URL: https:\/\/www.gov.za\/sites\/default\/files\/gcis_document\/201409\/3706726-11act4of2013protectionofpersonalinforcorrect.pdf [Accessed 28-11-2025]"},{"issue":"5","key":"R31","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1086\/381709","article-title":"What makes clinical research in developing countries ethical? The benchmarks of ethical research","volume":"189","author":"Emanuel","journal-title":"J Infect Dis"},{"key":"R32","unstructured":"South African Good Clinical Practice: Clinical Trial Guidelines. Department of Health, Republic of South Africa; 2020. URL: https:\/\/www.sahpra.org.za\/wp-content\/uploads\/2021\/06\/SA-GCP-2020_Final.pdf [Accessed 28-11-2025]"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:43:47Z","timestamp":1790797427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e93547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":32,"URL":"https:\/\/doi.org\/10.2196\/93547","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"v15i4e93547"}}